| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $86,588 | 1 | 13 |
Sells | $962,955 | 7 | 87 |
| Butler John P. | CEO and President | 1 | $86,588 | 1 | $474,414 | $-387,826 |
| Malabre Richard C | SVP, Chief Accounting Officer | 0 | $0 | 1 | $68,838 | $-68,838 |
| Burke Steven Keith | SVP, Chief Medical Officer | 0 | $0 | 1 | $94,045 | $-94,045 |
| Rucci Carolyn M. | SVP, Chief Legal Officer | 0 | $0 | 1 | $96,983 | $-96,983 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer | 0 | $0 | 2 | $110,763 | $-110,763 |
| Grund Nicholas | Chief Commercial Officer | 0 | $0 | 1 | $117,912 | $-117,912 |
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate …
Over the last 12 months, insiders at Akebia Therapeutics, Inc. have bought $86,588 and sold $962,955 worth of Akebia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akebia Therapeutics, Inc. have bought $86,588 and sold $641,124 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Butler John P. (CEO and President) — $86,588.
The last purchase of 69,270 shares for transaction amount of $86,588 was made by Butler John P. (CEO and President) on 2026‑03‑04.
| 2026-06-29 | Sale | Ostrowski Erik | SVP, CFO, CBO & Treasurer | 56,019 0.0209% | $1.11 | $62,181 | -17.23% | |
| 2026-03-04 | Butler John P. | CEO and President | 69,270 0.0261% | $1.25 | $86,588 | -16.80% | ||
| 2026-02-02 | Sale | Butler John P. | CEO and President | 341,305 0.1295% | $1.39 | $474,414 | -17.03% | |
| 2026-02-02 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 67,658 0.0257% | $1.39 | $94,045 | -17.03% | |
| 2026-02-02 | Sale | Ostrowski Erik | SVP, CFO, CBO & Treasurer | 34,951 0.0133% | $1.39 | $48,582 | -17.03% | |
| 2026-02-02 | Sale | Rucci Carolyn M. | SVP, Chief Legal Officer | 69,772 0.0265% | $1.39 | $96,983 | -17.03% | |
| 2026-02-02 | Sale | Grund Nicholas | Chief Commercial Officer | 84,829 0.0322% | $1.39 | $117,912 | -17.03% | |
| 2026-02-02 | Sale | Malabre Richard C | SVP, Chief Accounting Officer | 49,524 0.0188% | $1.39 | $68,838 | -17.03% | |
| 2025-06-30 | Sale | Ostrowski Erik | SVP, CFO, CBO & Treasurer | 41,314 0.0159% | $3.67 | $151,622 | -57.42% | |
| 2025-06-09 | Sale | Malabre Richard C | SVP, Chief Accounting Officer | 15,000 0.006% | $4.01 | $60,150 | -57.96% | |
| 2025-06-04 | Sale | Malabre Richard C | SVP, Chief Accounting Officer | 13,334 0.0049% | $3.53 | $47,069 | -55.49% | |
| 2025-03-03 | Sale | Butler John P. | CEO and President | 46,409 0.0217% | $1.83 | $84,928 | +35.00% | |
| 2025-03-03 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 7,144 0.0033% | $1.83 | $13,074 | +35.00% | |
| 2025-02-03 | Sale | Butler John P. | CEO and President | 144,250 0.062% | $2.10 | $302,925 | +14.62% | |
| 2025-02-03 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 50,506 0.0217% | $2.10 | $106,063 | +14.62% | |
| 2025-02-03 | Sale | Grund Nicholas | Chief Commercial Officer | 55,621 0.0239% | $2.10 | $116,804 | +14.62% | |
| 2025-02-03 | Sale | Malabre Richard C | SVP, Chief Accounting Officer | 30,202 0.013% | $2.10 | $63,424 | +14.62% | |
| 2024-05-13 | Sale | Dahan Michel | SVP, Chief Operating Officer | 34,840 0.0162% | $1.26 | $43,898 | +34.11% | |
| 2024-05-13 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 12,016 0.0056% | $1.26 | $15,140 | +34.11% | |
| 2024-02-29 | Sale | Butler John P. | CEO and President | 46,570 0.0249% | $1.58 | $73,581 | -7.28% |
| Butler John P. | CEO and President | 3367064 1.2151% | $2.44M | 7 | 12 | <0.0001% |
| Burke Steven Keith | SVP, Chief Medical Officer | 948432 0.3423% | $688,371.95 | 1 | 16 | |
| Satter Muneer A | director | 3037042 1.096% | $2.2M | 13 | 0 | <0.0001% |
| Novo A/S | 10 percent owner | 1516387 0.5472% | $1.1M | 1 | 0 | +3.18% |
| Hadas Nicole R. | SVP, Chief Legal Officer | 651243 0.235% | $472,672.17 | 1 | 23 | +3.18% |
| Novartis Bioventures Ltd | 10 percent owner | 182590 0.0659% | $132,523.82 | 1 | 0 | +3.18% |
| Amello Jason | SVP, CFO & Treasurer | 144642 0.0522% | $104,981.16 | 2 | 1 | <0.0001% |
| ADAMS ADRIAN | director | 63700 0.023% | $46,233.46 | 1 | 0 | |
| GILMAN STEVEN C | 43430 0.0157% | $31,521.49 | 1 | 3 | ||
| Smith Cynthia | director | 37833 0.0137% | $27,459.19 | 1 | 1 | |
| GOWEN MAXINE | director | 24133 0.0087% | $17,515.73 | 1 | 1 | <0.0001% |
| Renaud Ronald C JR | director | 5000 0.0018% | $3,629.00 | 1 | 0 | <0.0001% |
| WYZGA MICHAEL S | director | 1500 0.0005% | $1,088.70 | 1 | 0 | +3.18% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M |
| Increased Positions | 87 | +44.85% | 18M | +14.91% |
| Decreased Positions | 81 | -41.75% | 24M | -19.44% |
| New Positions | 23 | New | 3M | New |
| Sold Out Positions | 33 | Sold Out | 7M | Sold Out |
| Total Postitions | 200 | +3.09% | 118M | -4.52% |
| Blackrock, Inc. | $29,135.00 | 7.09% | 18.8M | +423,097 | +2.3% | 2025-09-30 |
| Vanguard Group Inc | $24,099.00 | 5.87% | 15.55M | +936,042 | +6.41% | 2025-09-30 |
| State Street Corp | $18,359.00 | 4.47% | 11.84M | +4M | +48.11% | 2025-09-30 |
| Geode Capital Management, Llc | $9,587.00 | 2.33% | 6.18M | +110,493 | +1.82% | 2025-09-30 |
| Morgan Stanley | $6,689.00 | 1.63% | 4.32M | -1M | -19.19% | 2025-09-30 |
| Renaissance Technologies Llc | $6,127.00 | 1.49% | 3.95M | -241,700 | -5.76% | 2025-09-30 |
| Ubs Group Ag | $5,652.00 | 1.38% | 3.65M | +3M | +470.2% | 2025-09-30 |
| Qube Research & Technologies Ltd | $4,970.00 | 1.21% | 3.21M | +1M | +87% | 2025-09-30 |
| Citadel Advisors Llc | $4,938.00 | 1.2% | 3.19M | +868,536 | +37.48% | 2025-09-30 |
| Mpm Bioimpact Llc | $4,478.00 | 1.09% | 2.89M | 0 | 0% | 2025-09-30 |